AB0278

INVESTIGATION OF POOR PROGNOSTIC FACTORS AMONG RHEUMATOID ARTHRITIS PATIENTS IN TURKBIO REGISTRY

N. Inanc¹, Z. Ertürk¹, G. Ozen¹, E. Dalkılıç², S.S. Koca³, G. Can⁴, A. Karatas³, Y. Pehlivan², A. Yazıcı⁵, S. Akar⁶, S. Senel⁷, B. Oz³, N. Akkoc⁸, H. Direskeneli¹. ¹Rheumatology, Marmara University School of Medicine, Istanbul; ²Rheumatology, Uludag University School of Medicine, Bursa; ³Rheumatology, Firat University School of Medicine, Elazığ; ⁴Rheumatology, Dokuz Eylül University School of Medicine, İzmir; ⁵Rheumatology, Kocaeli University School of Medicine, Kocaeli; ⁶Rheumatology, İzmir Katip Çelebi University School of Medicine, İzmir; ⁷Rheumatology, Erciyes University School of Medicine, Kayseri; ⁸Rheumatology, Private Practice, İzmir, Turkey

Background: TURKBIO is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011. Patients' data including age, sex, disease type and duration, and previous or current treatment with conventional (cs), targeted synthetic (ts) and biological (b) DMARDs were collected. In 2016, the EULAR RA management guideline recommended assessment of certain prognostic factors while deciding the treatment strategy after the first csDMARD failure.

Objectives: We examined the frequency and influence of these poor prognostic factors on treatment response in bDMARD and tsDMARD initiating RA patients enrolled in TURKBIO.

Methods: 898 biological and targeted synthetic DMARDs receiving RA patients from 8 participating centres of TURKBIO were studied. Seven investigated poor-prognostic factors were: ¹ Moderate to high disease activity (after csDMARD therapy), ² Elevated acute phase reactants, ³ High swollen joint counts (≥ 4), ⁴ High RF/ACPA titers, ⁵ Combinations of the above, ⁶ Erosions, ⁷ Failure of ≥ 2 csDMARDs. The frequencies of these factors at treatment initiation and influence of these on achievement of remission/remission+low disease activity (LDA) according to DAS28-CRP at the 6th month of treatment were evaluated in overall any bDMARD and tsDMARD-receiving patients.

Results: Among the prognostic factors; factors 1, 2, 4, 6 and 7 were found in over 60% of patients while factors 3 and 5 were present in about 30%. Factors 1 and 3 were more frequent in patients who were in moderate/high disease activity compared to those in remission +low disease activity (table 1). Same factors 1 and 3 were determined at higher percentage in non-remission than remission group (Factor 1: 93.4% vs. 82.2%, $p<0.001$; factor 3: 43% vs. 30.7%, $p=0.002$). These two factors were also significantly more frequent in patients withdrawn from the treatment (Factor 1: 93% vs. 85%, $p<0.001$; factor 3: 41% vs. 34%, $p=0.038$). In TNFi group besides factors 1 and 3, factors 5 and 7 were also significantly more frequent in non-remission group whereas, in the RTX group, only factor 1 was significantly more frequent in remission group. For the other bDMARDs and tsDMARD (ABA, TCZ, TOFA), we did not find any difference in poor prognostic factors among patients who did achieve remission and did not.

Abstract AB0278 – Table 1. Frequencies of poor prognostic factors in RA patients initiating bDMARDs and tsDMARD by disease activity* at the 6th month of treatment

Factors	Remission+low disease activity, %	Moderate+high disease activity, %	P value
Factor 1: Moderate to high disease activity (after csDMARD therapy)	95.9	83.6	<0.001
Factor 2: Elevated acute phase reactants	100	99.5	z
Factor 3: High swollen joint counts (≥ 4)	47.1	31.7	<0.001
Factor 4: High RF/ACPA titers	68.3	71.9	0.465
Factor 5: Combinations of the factors 1, 2, 3, 4	31.3	25.9	0.284
Factor 6: Erosions	56.5	65.6	0.332
Factor 7: Failure of ≥ 2 csDMARDs	69.4	69	0.918

* Disease activity was assessed by using DAS28-CRP at the 6th month of treatment

Conclusions: Five of the seven poor prognostic factors were detected more than half of the RA patients at bDMARD and tsDMARD initiation in TURKBIO. Patients with poor prognostic factors especially factors 1 and 3 achieved remission less frequently. Additionally, there was a relationship between bDMARDs and tsDMARD withdrawal and factors 1 and 3. The influence of these factors was mainly observed in TNFi receiving group.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4259

AB0279

RAPID3 IS NOT LONGITUDINALLY ASSOCIATED WITH DAS28-ESR IN PATIENTS WITH RHEUMATOID ARTHRITIS

N. Boone¹, A. Sepriano^{2,3}, R. Janknegt¹, H. van der Kuy⁴, R. Peeters^{5,6}, R. Landewe⁵. ¹Department of Clinical Pharmacology and Toxicology, Zuyderland Medical Centre, Sittard-Geleen; ²Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ³Nova Medical School, Universidade Nova de Lisboa, Lisboa, Portugal; ⁴Department of Clinical Pharmacy, Erasmus Medical Centre, Rotterdam; ⁵Department of Rheumatology, Zuyderland Medical Centre, Sittard-Geleen; ⁶Amsterdam Rheumatology and Immunology Centre, Amsterdam, Netherlands

Background: The Routine Assessment of Patient Index Data 3 (RAPID3) is a patient reported outcome (PRO) proposed to conveniently measure disease activity in rheumatoid arthritis (RA) based on functioning, pain and global health scores. DAS28 (including PRO and objective measures) is the most frequently used score in clinical practice and research for that purpose^[1]. It has been suggested that composite scores measuring PROs only (e.g. RAPID3) might add to the assessment of disease activity over time but this claim is yet to be formally tested.

Objectives: In this study we evaluated a possible longitudinal association between RAPID3 and DAS28-ESR (including individual components) in patients with RA from daily clinical practice.

Methods: Adult patients with RA on stable treatment with either conventional synthetic disease modifying drugs (csDMARDs) and/or biologic DMARDs (bDMARDs), followed in one centre, were included. Patients were followed every 3 months up to 3 years and in each visit both clinical and medication data was collected by rheumatologists/research nurses. The longitudinal association between RAPID3 (range: 0–30) with DAS28-ESR and its individual components [tender joint count (TJC; 0–28); swollen joint count (SJC; 0–28); patient global assessment (PGA; 0–10) and ESR (mm/h)] was tested (in separate models) by longitudinal generalised estimating equations (GEE) with auto-regression. Interactions between RAPID3 with gender (male vs female), VAS pain (≥ 5 vs <5), PGA (≥ 5 vs <5) and age (≥ 62 vs <62) at baseline were tested and if significant ($p<0.20$) and clinically relevant each model (either using DAS28 or its individual components as outcome) was stratified accordingly.

Results: In total, 330 patients were included [mean (SD) age: 62¹² years, 68% female, baseline mean (SD) DAS28: 3.3 (1.4) and RAPID3: 11.5 (6)]. The mean (SD) follow-up period was 10.7 (9.7) months. Although, statistically significant, we only found a poor association between RAPID3 and DAS28-ESR over time (table 1). An increase of one unit in RAPID3 (0–30) was associated with an increase of only 0.1 units of DAS28-ESR. Gender, age, PGA and VAS pain were not found to meaningfully modify the association between RAPID3 and DAS28. A far stronger association was found between RAPID3 and the 'subjective components' [TJC: $\beta=0.30$ (95%: 0.20; 0.39); and PGA: $\beta=0.31$ (95%: 0.28; 0.35)] of DAS28-ESR, as compared to the 'objective components' (i.e., SJC and ESR; the latter only significant in males) (table 1).

Abstract AB0279 – Table 1. Longitudinal association between RAPID3 and DAS28 and each individual component

	Main effect β (95% CI)	Males β (95% CI)	Females β (95% CI)
DAS28 ESR	0.10 (0.10; 0.10)	NA	NA
Swollen joint count	0.10 (0.06; 0.14)	NA	NA
ESR	NA	0.12 (0.03; 0.22)	-0.10 (-0.16; 0.14)
Tender joint count	0.30 (0.20; 0.39)	NA	NA
PGA	0.31 (0.28; 0.35)	NA	NA

Each line is a separate model; NA, not applicable.

Conclusions: There is no meaningful longitudinal association between RAPID3 and DAS28. DAS28 captures objective signs of disease activity over time in RA while RAPID3 only captures subjective symptoms of RA.

REFERENCE:

- [1] Van der Heijde DM, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. *J Rheumatol* 1993;20:579–581.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6910